Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat

Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.

Pyramid, cylinder and a sphere in perfect balance
• Source: shutterstock.com

Abbott weathered the enormous challenges of 2020 with a unique diversified business structure and continuous investment in innovation.

“In normal times, [our business structure] maximizes our growth opportunities, and during the pandemic, it has been tested by a global crisis and proven to be highly resilient,” CEO Robert Ford said during

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from In Vitro Diagnostics

More from Diagnostics